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Abstract
Background: Data suggest that antibody responses to malaria parasites merozoite antigens are
generally short-lived and this has implications for serological studies and malaria vaccine designs.
However, precise data on the kinetics of these responses is lacking.
Methods: IgG1 and IgG3 responses to five recombinant Plasmodium falciparum merozoite antigens
(MSP-119, MSP-2 type A and B, AMA-1 ectodomain and EBA-175 region II) among Kenyan children
were monitored using ELISA for 12 weeks after an acute episode of malaria and their half-lives
estimated using an exponential decay model.
Results: The responses peaked mainly at week 1 and then decayed rapidly to very low levels within
6 weeks. Estimation of the half-lives of 40 IgG1 responses yielded a mean half-life of 9.8 days (95%
CI: 7.6 – 12.0) while for 16 IgG3 responses it was 6.1 days (95% CI: 3.7 – 8.4), periods that are
shorter than those normally described for the catabolic half-life of these antibody subclasses.
Conclusion: This study indicates antibodies against merozoite antigens have very short half-lives
and this has to be taken into account when designing serological studies and vaccines based on the
antigens.
Background
An effective malaria vaccine is urgently needed, but to
date it remains elusive. A common way of trying to estab-
lish if a given malaria parasite antigen is a good candidate
for a malaria vaccine is by determining if an with protec-
tion against subsequent infections of malaria. However, a
number of studies suggest that naturally acquired
responses to malaria merozoite antigens are short-lived.
Among the majority of people living in endemic areas,
levels of antibodies to merozoite antigens appear to vary
with the levels of malaria transmission i.e. they are highest
during periods of intense transmission and lowest or
undetectable at the end of periods of low transmission [1-
3]. Further, levels of antibodies to merozoite antigens
often tend to be higher in individuals who also have
malaria parasites at the time when their antibodies are
measured than in those without parasites [2,4-6].
The implication of these observations is important as they
suggests that during serological surveys, individuals who
can nonetheless mount a rapid secondary antibody
response to malaria antigens upon re-infection are likely
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to be classified as antibody negative depending on how
recent their last malaria infection was. Conversely, indi-
viduals who are positive at the survey may be negative by
the time they encounter the next infection. If indeed the
antibodies responses are very brief, then data from longi-
tudinal studies with long intervals between sampling days
will not reflect well the dynamics of the responses. Unfor-
tunately, estimates of the half-lives of antibody responses
to malaria that can help guide the design of such studies
are lacking. In this study, a closely spaced sampling sched-
ule was used to monitor the kinetics of antibody
responses to five recombinant Plasmodium falciparum
merozoite antigens among Kenyan children recovering
from a clinical infection of malaria and the data used to
estimate the half-life of the responses. The results of the
study indicated that both IgG1 and IgG3 antibodies to
merozoite antigens have very short half-lives.
Methods
Study population and blood sampling
This study was carried out at Kilifi District Hospital (KDH)
on the Kenyan coast. Ethical clearance for the study was
given by the Kenya Medical Research Institute ethics
review board. Forty eight children admitted to the pediat-
ric ward of KDH with a primary diagnosis of malaria, but
who did not fulfill the World Health Organization criteria
for severe malaria [7], were recruited, if their guardian
gave written consent. A venous blood sample was taken
from each child at recruitment and, subsequently, at as
many of the time points as possible 1, 2, 3, 6, 9, and 12
wks after treatment with sulphadoxine/pyrimethamine
(SP). The samples were centrifuged at 700 × g for 5 min to
obtain plasma, which was stored at 20°C. The children
were examined by a clinician and a thick malaria film pre-
pared during the follow-up visits or any other time during
the study when they were unwell. Malaria treatment (SP)
was given for parasitaemia in the presence of fever (axil-
lary temperature ≥ 37.5°C). Seven children from whom
weeks 1 and 2 samples could not be obtained were con-
sidered lost to follow up, so the cohort for analysis com-
prised 41 children.
ELISA
IgG1 and IgG3 antibody reactivity to recombinant ectodo-
main of P. falciparum apical merozoite antigen 1(AMA-1),
the 11 kDa carboxyl portion of merozoite surface antigen
1 (MSP-119), region II of the 175 kDa erythrocytes binding
antigen (EBA-175 RII), and two recombinant proteins
representing the two major allelic types of MSP-2 was
assessed in plasma samples from 41 children (age range =
7 – 107 months, median = 34 months). Levels of IgM
reactivity against the two allelic types of MSP-2 were also
assessed. The AMA-1 antigen and EBA-175 region II were
kind gifts from Sheetij Dutta and Arnoldo Barbosa
(WRAIR, Maryland, USA) and have been previously
described [8,9], while MSP-119 and MSP-2 proteins were
provided by Jana McBride and David Cavanagh (Univer-
sity of Edinburgh, UK) and have also been previously
described [10,11]. Plasma was assayed at 1:4000 dilution
for antibodies to AMA-1 and at 1:500 for antibodies to the
other antigens using ELISA protocols described previously
[3,11,12]. Briefly, the wells of 96-well plates (Immulon4;
Dynatech, Chantilly, VA) were coated overnight at 4°C
with either 50 ng (MSP-119 and MSP-2) or 100 ng (EBA-
175 and AMA-1) of antigen in sodium carbonate buffer
(pH 9.3), washed, and then blocked with 1% skimmed
milk in coating buffer for 5 h and washed again. The wells
were subsequently incubated overnight at 4°C with 100
µl of plasma diluted in 1% skimmed milk, followed by a
three-hour incubation with 100 µl of horseradish peroxi-
dase-conjugated rabbit antibodies against human anti-
bodies (Dako Ltd, Cambridge, UK) at 1/1000 for anti-
human IgG1 and IgG3 or 1/5000 for anti-human IgM,
with washing between the incubations. Colour was devel-
oped with o-phenylenediamine, the reaction stopped after
15 minutes with 20 µl of 2 M H2SO4, and absorbance was
measured as optical density (OD) at 492 nm. All samples
were simultaneously assayed in duplicate for IgG1 and
IgG3 antibodies against a given antigen. Absorbance read-
ings for responses against MSP-119 and MSP-2 antigens
were corrected for responses to the GST fusion carrier by
deducting the absorbance of the same plasma assayed
against GST alone. The cut-off for absorbance readings for
each antigen was set as mean plus three standard devia-
tions of absorbance readings of sera from eight Europeans
without any history of malaria infection. In order to con-
vert absorbance to concentration (µg/ml), plates were
coated with purified human myeloma proteins IgG1, and
IgG3 (at threefold serial dilutions from 10 to 5.1 × 10-4 µg/
ml).
The resulting standard absorbance versus concentration
curves were used for interpolation of the absorbances of
the plasma samples to estimate concentrations.
Estimating the half-life of the responses
To estimate the half-life of antibody responses to the test
antigens, response profiles that showed a decline of anti-
body levels over at least four consecutive sampling points
were selected and the decay phase analysed up to the sam-
pling point where the ODs were too low for concentration
to be estimated from standard curves, or the decline was
obviously interrupted by boosting. After conversion of
absorbance to concentration as described above, one-
phase exponential decay curves defined by the equation
below were fitted to the decay phase of the selected
response profiles using Graphpad Prism software ver. 3.2
(San Diego, USA).
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Where [C]0 and [C]t are concentrations at time 0 and t
respectively, k is a rate constant and plateau is the concen-
tration at the end of the decay and half-life of the decay
(t1/2) is calculated as follows:
Assessing factors that might influence the kinetics and half-
life of responses
Association between kinetics half-life of the responses and
age of responder or peak level of antibodies at the begin-
ning of the decay was assessed by linear regression using
Stata ver. 8 (Stata Corporation, TX, USA), while differ-
ences between half-lives of response to the various test
antigens was assessed using one-way ANOVA. In addition,
ANOVA was used to test if the mean level of responses to
the test antigens differed between individuals. The profiles
were then grouped together depending on whether or not
they had peaked before the child presented to hospital,
and the mean half-lives of the groups compared using a
student t-test.
Results
Antibody responses to P. falciparum antigens in the study 
children
There was considerable variation in the children's overall
pattern of responses to the five test antigens but for each
antigen, the children generally responded in one of three
ways. Either, (1) they already had moderate to high levels
of antibodies to the antigen by the time they presented to
hospital (e.g. IgG1 responses to MSP-119 in subjects 23,
36, 38, 40, 41,47, 48 and 56, Figure 1a; IgG3 response to
MSP-2 in subjects 10, 44, and 56, Figure 2) or, (2) they
presented with low levels of antibodies but made sharp
responses that peaked one week after the episode and
then declined rapidly (IgG1 responses to MSP-2 in the
plots in Figure 1b) or, (3) they made only very low
responses (many of the responses plotted in Figures 1a
and 1b and Figure 2). IgM antibodies to the two MSP-2
antigens was also assayed to see if the children were mak-
ing primary responses. Only in two subjects did the IgM
absorbance rise above the cut off value during the study
period: in subject 28 anti-MSP-2 type B IgM peaked at
week one with an absorbance of 0.74, which was much
lower than that of the strongest IgG responses that the
child made (absorbance of 2.42 for IgG1 to MSP-2 type
A); child number 44 had anti-MSP-2-type B IgM absorb-
ance of 0.74 at presentation, which was also much lower
than the strongest IgG response (absorbance of 2.55 for
IgG1 to MSP-2 type B).
Boosting of responses over time
After peaking, the responses generally showed a steady
decline but eventually some boosting was observed.
Boosting of responses to individual antigens was often
associated with the appearance of malaria parasites in the
IgG3), but not always (in 15 instances for IgG1, and six for
IgG3). Only in 10 of the 43 individual antigen-specific
boosting instances were IgG1 responses boosted to simi-
lar or higher levels than the initial peak (for example, anti-
MSP-2 type A response in subject 38, anti-EBA-175
response in subject 47, Figure 1a), and only five of 15
instances did such boosting occur in the case of IgG3
responses (e.g. anti-MSP-2 type B response in subject 47,
Figure 2). 28/41 (68%) children became positive for
malaria parasites at one or more sampling time points,
mainly 5 weeks or longer after the clinical episode.
Response profiles selected for half-life estimation
Sixty nine IgG1 response profiles from 28 children
showed monophasic decay over four consecutive time
points. Of these, 40 profiles from 23 children had four
consecutive sampling points with absorbance within the
interpolation range of the standard curves and were used
in the half-life estimation. Of the 26 IgG3 response pro-
files from 15 children that exhibited monophasic decay
over four consecutive time points, 16 profiles from nine
children had absorbance within interpolation range of the
standard curve, and were used for analysis of half-life.
Half-life of antibody responses to the test antigens
The exponential decay model used had a fit of R2 > 0.90
for the profiles analysed. The mean half-lives of the 40
IgG1 responses analysed individually was 9.8 days (95%
confidence interval [CI]: 7.6 – 12.0). There was no associ-
ation between half-life and age (r2 = 0.055, P = 0.130),
peak level of antibody (r2 = 0.003, P = 0.748), or antigen
specificity (F = 0.547, P = 0.653). The half-lives of the
responses did not differ significantly between different
individuals (F = 2.198, P = 0.140; ANOVA on data from
five individuals for each of whom the half-lives of
responses to three antigens were estimated). The mean
half-life of the IgG3 responses analysed was lower (6.1
days, 95% CI: 3.7 – 8.4) than that of IgG1 but not signifi-
cantly (Mann-Whitney U test, P = 0.424). As with IgG1,
there was no association between half-life and age (r2 =
0.13, P = 0.210), peak levels of antibody (r2 = 0.74, P =
0.273), or antigen specificities (F = 0.448, P = 0.647) (Fig-
ure 3). For both isotypes, the small number of data points
analysed for each profile did not allow reliable estimation
of the confidence intervals of the half-lives within each
individual child.
Half-life of responses in relation to status at presentation 
to hospital
The profiles were grouped depending on whether or not
they had peaked by the time the child was presented to
hospital and compared their mean half-lives. IgG1 pro-
files which peaked before presentation to hospital (n = 8)
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Examples of absorbance profiles of IgG1 response to the test antigens among the study children Figure 1
Examples of  absorbance profiles of IgG1 response to the test  antigens among the study children.  Day 0 is the 
day of presentation to  hospital.  The number above each plot is the child's study number.  a)  Children who had moderate to 
high level of antibodies to one or more  antigens at presentation to hospital.  b) Children who made a distinct  responses to 
one or more antigens after presentation to hospital.  For  the responses whose half-life was estimated, the sampling points 
used in  the estimation are joined by a bold line.  Responses that peaked beyond  the interpolation range of the standard curve 
are plotted in dotted  lines.  The solid triangles below the plots indicate time points when  the children were positive for 
malaria parasites.  
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had a longer mean half-life (13.1 days [95% CI: 8.2 –
21.4]) than those that peaked after presentation (n = 32)
(8.9 days [95% CI: 5.5–10.8]) but the difference was not
significant (P = 0.17). The mean half-life of IgG3
responses that peaked before presentation to hospital (n =
5) was 7.3 days (95% CI: 5.0 9.5), while that of the
responses that peak post presentation (n = 10) was 8.1
days (95% CI: 4.8 – 11.5), a small difference that was not
significant (P = 0.685)
Correlation between half-life of responses within the same 
child
Data from 11 children where responses to two or more
antigens were analysed for half-life was used to determine
the correlation between the half-life of responses to differ-
ent antigens within the same child. A high level of corre-
lation between responses to different antigens by the same
child was observed (R2 = 0.63, P = 0.004).
Discussion
Estimating the half-life of antibody responses to malaria
antigens among residents of malaria endemic areas is dif-
Half-lives of individual IgG1 and IgG3 responses to the test  antigens in days Figure 3
Half-lives of individual IgG1 and IgG3 responses to 
the test antigens in days. Among some children, response 
profile to only one of the four test antigens fulfilled the crite-
ria for half-life analysis while among the other children, pro-
files of responses to two or more antigens were analysed.
Study number
-M S P 1 - 1 9 -M S P 2 - t y p e  1 -M S P 2 - t y p e  1 - EBA175 RII -A M A 1
IgG3 antibodies responses to the test antigens among children where some of the profiles were used in half-life estimation Figure 2
IgG3 antibodies responses to the test antigens among children  where some of the profiles were used in half-
life estimation.  Day 0 is  the day of presentation to hospital.  The number above the plot is the  child's study number.  The 
sampling points used in half-life  estimation are joined with a bold line.  The solid triangles below the  plots indicate time points 
when the children were positive for malaria  parasites.  
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ficult as the kinetics of the antibodies are continually
altered by reinfection. In this study, eventual boosting of
the initial responses was evident in many of the children
even in the absence of patent re-parasitization. As such,
half-lives could only be estimated for those responses that
showed no obvious boosting over at least four time
points. However, it is still possible that the half-life esti-
mates obtained may still have been subtly affected by sub-
patent of re-parasitization. In addition the half-life of the
some of the profiles that were not analysed because they
did not meet the inclusion criteria may have been differ-
ent from those estimates obtained but it was not possible
to clarify this. As such, a future study is being planned that
will include a group of children who are kept parasite-free
over study period by chemoprophylaxis. Nevertheless,
this study shows that among Kenyan children recovering
from clinical malaria, antibody responses to P. falciparum
merozoite antigens particularly IgG1 often have very short
half-lives. While the estimated mean half-life of the IgG3
antibodies (6 days) was similar to that of antibodies
injected into healthy adults (8 days) [13], that of IgG1
(9.8 days) was about half that of the exogenous antibod-
ies (21–23 days).
Such short half-lives could explain observations from pre-
vious longitudinal studies that reported a rapid decline of
antibodies to malaria antigens within a few months of
malaria treatment. For instance, 44% of Brazilian individ-
uals who made antibodies to the C-terminal fragment of
P. vivax merozoite surface protein 1 (MSP-119) during a
clinical episode of malaria became sero-negative within
two months of treatment [6]. Similarly, antibodies to P.
falciparum MSP1 and rhoptry associated protein 1(RAP-1)
in Sudanese individuals often last for less than three
months after treatment for clinical malaria [3,14].
Data on the half-lives of natural responses to other infec-
tious agents such as bacteria are generally lacking and it is
not possible to say if the short-lives observed here are
unique to malaria or common to acute infection by differ-
ent pathogens. Future studies will have to incorporate
patients with other conditions for comparison. On the
other hand, antibodies responses to viral infections and
vaccines such as measles, appear to last for many years
[15,16] although possibly sustained by persistent cryptic
viral particles [17]. Interestingly, malaria chemoprophy-
laxis was associated with a slower rate of decay of antibod-
ies to a meningococcal vaccine among Gambia children
[18] suggesting that acute malaria might affect the longev-
ity of antibodies universally.
Although the half-life of IgG1 is usually cited as 21 days
[13], early studies showed the half-life is inversely related
to serum concentration and for IgG1, IgG 2 and IgG 4 it
may vary from over 70 days to 11 days [19]. Malaria epi-
sodes are associated with raised concentrations of both
specific and polyclonal of antibodies [20-22] and this
may, in part, explain the reduced IgG1 antibody half-lives
observed. However, in some children, the antibodies had
extremely short half-lives suggesting that other processes,
besides ordinary catabolism, may be contributing to the
decay. The clearance of immune complexes whose levels
and rate of clearance by macrophages are raised during
acute episodes of malaria [23,24] is a possible other proc-
ess, but its contribution is not clear currently.
Since in natural responses, the kinetics of antibodies is a
balance between production and decay the profiles
observed in this study suggest that production of antibody
against merozoite antigens is not sustained following an
acute episode of malaria. Antibody production can be sus-
tained through re-stimulation of memory B cells by per-
sistent antigens [25,26] or by non-proliferating long-lived
plasma cells [27,28]. In mice, long-lived plasma cells sur-
vive mainly in the bone marrow [28-30] and have a half-
life of about five months [31], compared to a lifespan of
3–5 days for short-lived plasma cells [29]. Thus, the kinet-
ics of the antibody responses described here are consistent
with production by short-lived plasma cells. Clearly fur-
ther studies on the effects of acute episodes of malaria on
commitment of plasma cells to the memory or long life
compartment is required. For example, how does the
adherence of red cells infected with either sexual or
mature asexual stages of malaria parasites to bone marrow
stromal cells [32] affect the survival of long-lived plasma
cells?
Interestingly, in many instances, re-parasitization after the
episode did not boost the initial responses or only did so
mildly. While polymorphism in the new infection might
explain some of the failure, the fact that boosting occurred
in many instances but only to a lower level than the initial
responses suggests that there may be a period of suppres-
sion of antibody responses following a clinical episode of
malaria. Reduced reactivity to viral vaccines during
malaria episodes and recovery of reactivity following
malaria treatment has been reported among Nigerian chil-
dren [33].
Conclusion
This study shows that following an acute episode of
malaria in children living in an endemic area, antibody
responses to malaria merozoite often have very short half-
lives; less than those reported for normal antibody clear-
ance. This has implication for studies monitoring
responses to these antigens and indicates the need for
closely spaced sampling within the first few weeks of an
episode. Further studies on the fate of antibody producing
cells following a malaria episode are required in order to
elucidate the mechanism underlying this brevity. In addi-Malaria Journal 2007, 6:82 http://www.malariajournal.com/content/6/1/82
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tion, it is important to establish whether the brevity of the
responses is due to malaria disease processes or whether it
is inherent to the antigens. Would vaccines based on the
antigens also induce short-lived responses in healthy chil-
dren, and would this compromise their use, or would
memory B cell populations be adequate for a sufficient
antibody response upon infection?
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